A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas

HAEMATOLOGICA

FERRATA STORTI FOUNDATION

1. Takeda Pharmaceuticals Co, Ltd.
2. Korean Health Technology R&D Project Strategic Center of Cell and Bio Therapy for Heart, Diabetes & Cancer through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health Welfare (MHW) [HI-17C-2085]